Glass Health Programs Inc is a licensed substance use treatment provider in Baltimore, MD, listed in the SAMHSA treatment directory. Outpatient care is offered, so clients can keep living at home between scheduled sessions. On site detox services are available, so withdrawal can be managed before treatment begins. Methadone is available as part of medication assisted treatment for opioid use disorder. Buprenorphine (Suboxone) is offered to reduce opioid cravings and lower relapse and overdose risk. The program treats co-occurring mental health conditions alongside addiction. The facility reports accepting Medicaid. Private health insurance is accepted. It serves young adults, adults, seniors.
Availability and current services change often. Call (888) 470-5244
and we will help you confirm openings, insurance, and next steps.
Levels of care
OutpatientOutpatient detoxificationOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatment
Type of care
Substance use treatmentDetoxification
Medications
Methadone used in TreatmentBuprenorphine used in Treatment
Detox services
Benzodiazepines DetoxificationCocaine DetoxificationOpioids detoxificationMedication routinely used during detoxification
Payment accepted
Federal, or any government funding for substance use treatment programsMedicareMedicaidFederal military insurance (e.g., TRICARE)Private health insuranceCash or self-payment
Ages served
Young AdultsAdultsSeniors
Accreditation
State substance use treatment agencyState department of healthCommission on Accreditation of Rehabilitation Facilities (CARF)SAMHSA certification for opioid treatment program (OTP)Drug Enforcement Agency (DEA)
Free & confidential, 24/7
Not sure which program fits? Talk it through with someone who can help.
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare
1111 North Charles Street, 5th Floor, Baltimore, MD 21201
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare